<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599402</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-401</org_study_id>
    <secondary_id>2015-001274-17</secondary_id>
    <nct_id>NCT02599402</nct_id>
  </id_info>
  <brief_title>Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma</brief_title>
  <acronym>CheckMate 401</acronym>
  <official_title>Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of combination treatment of Nivolumab&#xD;
      with Ipilimumab followed by Nivolumab monotherapy in patients with previously untreated&#xD;
      advanced Melanoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2015</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">February 10, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Participants With High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events</measure>
    <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
    <description>Incidence of participants with high-grade (CTCAE v4.0 grade 3-5) treatment-related, select adverse events of potentially immune-mediated etiology including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Participants With All High-Grade (Grades 3-5) Select Adverse Events</measure>
    <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
    <description>Incidence of participants with high-grade (grade 3-5) select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, infusion-related, or hypersensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Onset (Grades 3-4) of Select Adverse Events</measure>
    <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
    <description>Median time to onset (grades 3-4) of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Resolution (Grades 3-4) of Select Adverse Events</measure>
    <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
    <description>Median time to resolution (Grades 3-4) of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of an Adverse Event (AE)</measure>
    <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
    <description>Resolution of an adverse event (AE) is defined as a participant experiencing complete resolution or improvement to the baseline of any grade AE including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 37 months</time_frame>
    <description>Overall survival is defined from the time of first dosing date to the date of death. A participant who has not died will be censored at the last known date alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Participants With Adverse Events</measure>
    <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
    <description>The assessment of safety is measured by the incidence of participants who experienced any grade of adverse events (AEs), treatment-related AEs, serious adverse events (SAEs), and deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Participants With Select Adverse Events</measure>
    <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
    <description>The assessment of safety is measured by the incidence of participants who experienced any grade of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Participants With Laboratory Abnormalities - Liver</measure>
    <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
    <description>Safety assessment is measured by the incidence of participants who experienced a liver laboratory abnormality in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Upper Limit of Normal (ULN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Participants With Laboratory Abnormalities - Thyroid</measure>
    <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
    <description>Safety assessment is measured by the incidence of participants who experienced a thyroid laboratory abnormality in Free T3 (FT3), Free T4 (FT4), Lower Limit of Normal (LLN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 37 months</time_frame>
    <description>Objective response rate is defined as the percentage of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of all treated participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to approximately 37 months</time_frame>
    <description>Progression free survival per investigator assessment is defined as radiological evidence of progression, significant clinical symptomatic progression, or the need to introduce a non-study drug therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">533</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Combination therapy: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab + Ipilimumab specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy: Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Combination therapy: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Monotherapy: Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Combination therapy: Nivolumab + Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Potential subjects must have advanced Melanoma (stage III or IV as confirmed by&#xD;
             biopsy) with spread to other sites in the body and unable to be removed by surgery.&#xD;
&#xD;
          -  Potential subjects must be newly diagnosed with advanced melanoma and received no&#xD;
             treatment for the advanced disease.&#xD;
&#xD;
        NOTE: Prior adjuvant or neoadjuvant melanoma therapy (including anti-CTLA-4, anti-PD-1,&#xD;
        anti-PD-L1, anti-PD-L2, or any other antibody or drug specifically targeting T-cell&#xD;
        costimulation or checkpoint pathways, such as anti-CD-137) is permitted if the therapy was&#xD;
        used in the adjuvant or neoadjuvant setting but not in the metastatic setting. These drugs&#xD;
        must be discontinued 6 months prior to study entry and the side effects related to the&#xD;
        prior therapy resolved.&#xD;
&#xD;
          -  Potential subjects (with disease spread to brain) who previously received primary&#xD;
             treatment are permitted if there was no evidence of disease as confirmed by the MRI&#xD;
             (at least 2 weeks after the primary treatment is complete and with in 6 weeks of the&#xD;
             first dose of the study drug). Potential subjects must not have received intravenous&#xD;
             steroid treatment (&gt;10 mg/day) intravenously for at least 2 weeks prior to study drug&#xD;
             administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Leptomenigeal metastases&#xD;
&#xD;
          -  Subjects with autoimmune disease. Subjects with Type I diabetes mellitus,&#xD;
             hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo,&#xD;
             psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected&#xD;
             to recur in the absence of an external trigger are permitted to enroll.&#xD;
&#xD;
          -  All side effects from previous primary treatments other than alopecia, fatigue, or&#xD;
             peripheral neuropathy must have resolved to Grade 1 or baseline before administration&#xD;
             of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gateshead</city>
        <state>New South Wales</state>
        <zip>2290</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tiwi</city>
        <state>Northern Territory</state>
        <zip>0810</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5402</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Angers Cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grenoble Cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Le Mans Cedex 9</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pierre Benite Cedax</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>TOULOUSE Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-palladium</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dresden</city>
        <zip>01277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erfurt</city>
        <zip>99028</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stade</city>
        <zip>21682</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Galway</city>
        <zip>ST4 6QG</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Eskilstuna</city>
        <zip>631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gävle</city>
        <zip>SE-80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Karlskrona</city>
        <zip>371 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Linköping</city>
        <zip>SE-58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sundsvall</city>
        <zip>164 40</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vasteras</city>
        <zip>721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Växjö</city>
        <zip>SE-35185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lausanne</city>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Headington</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <results_first_submitted>April 23, 2021</results_first_submitted>
  <results_first_submitted_qc>May 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 15, 2021</results_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02599402/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02599402/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>533 participants treated</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nivolumab + Ipilimumab Total</title>
          <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240 mg) IV Q2W up to 21 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="533"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="533"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug toxicity</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event unrelated to study drug</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant request to discontinue study treatment</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Maximum Clinical Benefit</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant no longer met study criteria</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nivolumab + Ipilimumab Total</title>
          <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240 mg) IV Q2W up to 21 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="533"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="13.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="515"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="521"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Participants With High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events</title>
        <description>Incidence of participants with high-grade (CTCAE v4.0 grade 3-5) treatment-related, select adverse events of potentially immune-mediated etiology including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
        <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
        <group_list>
          <group group_id="O1">
            <title>Nivolumab + Ipilimumab Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab + Ipilimumab ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1 subgroup</description>
          </group>
          <group group_id="O3">
            <title>Nivolumab + Ipilimumab ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2 subgroup</description>
          </group>
          <group group_id="O4">
            <title>Nivolumab + Ipilimumab Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Brain Metastasis subgroup</description>
          </group>
          <group group_id="O5">
            <title>Nivolumab + Ipilimumab Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Mucosal</description>
          </group>
          <group group_id="O6">
            <title>Nivolumab + Ipilimumab Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Ocular/Uveal</description>
          </group>
          <group group_id="O7">
            <title>Nivolumab + Ipilimumab Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Cutaneous</description>
          </group>
          <group group_id="O8">
            <title>Nivolumab + Ipilimumab Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Acral</description>
          </group>
          <group group_id="O9">
            <title>Nivolumab + Ipilimumab Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Other</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Participants With High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events</title>
          <description>Incidence of participants with high-grade (CTCAE v4.0 grade 3-5) treatment-related, select adverse events of potentially immune-mediated etiology including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulmonary: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="57"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="43"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/Infusion Reaction: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/Infusion Reaction: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Participants With All High-Grade (Grades 3-5) Select Adverse Events</title>
        <description>Incidence of participants with high-grade (grade 3-5) select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, infusion-related, or hypersensitivity</description>
        <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Participants With All High-Grade (Grades 3-5) Select Adverse Events</title>
          <description>Incidence of participants with high-grade (grade 3-5) select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, infusion-related, or hypersensitivity</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulmonary: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="61"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="67"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic: Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/Infusion Reaction: Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Onset (Grades 3-4) of Select Adverse Events</title>
        <description>Median time to onset (grades 3-4) of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
        <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one select adverse event from the category</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Onset (Grades 3-4) of Select Adverse Events</title>
          <description>Median time to onset (grades 3-4) of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one select adverse event from the category</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulmonary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" lower_limit="12" upper_limit="783"/>
                    <measurement group_id="O2" value="51.5" lower_limit="12" upper_limit="783"/>
                    <measurement group_id="O6" value="51.0" lower_limit="51" upper_limit="51"/>
                    <measurement group_id="O7" value="52.0" lower_limit="12" upper_limit="783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="61"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" lower_limit="7" upper_limit="582"/>
                    <measurement group_id="O2" value="49.0" lower_limit="7" upper_limit="582"/>
                    <measurement group_id="O3" value="61.0" lower_limit="8" upper_limit="91"/>
                    <measurement group_id="O4" value="83.0" lower_limit="35" upper_limit="543"/>
                    <measurement group_id="O5" value="42.5" lower_limit="27" upper_limit="543"/>
                    <measurement group_id="O6" value="39.0" lower_limit="20" upper_limit="95"/>
                    <measurement group_id="O7" value="49.0" lower_limit="7" upper_limit="582"/>
                    <measurement group_id="O8" value="7.0" lower_limit="7" upper_limit="7"/>
                    <measurement group_id="O9" value="79.0" lower_limit="8" upper_limit="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="4" upper_limit="670"/>
                    <measurement group_id="O2" value="35.0" lower_limit="4" upper_limit="404"/>
                    <measurement group_id="O3" value="17.5" lower_limit="7" upper_limit="670"/>
                    <measurement group_id="O4" value="14.0" lower_limit="14" upper_limit="14"/>
                    <measurement group_id="O5" value="48.0" lower_limit="8" upper_limit="69"/>
                    <measurement group_id="O6" value="36.5" lower_limit="14" upper_limit="127"/>
                    <measurement group_id="O7" value="17.5" lower_limit="4" upper_limit="670"/>
                    <measurement group_id="O8" value="89.0" lower_limit="89" upper_limit="89"/>
                    <measurement group_id="O9" value="100.0" lower_limit="10" upper_limit="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" lower_limit="6" upper_limit="540"/>
                    <measurement group_id="O2" value="43.0" lower_limit="6" upper_limit="223"/>
                    <measurement group_id="O3" value="540.0" lower_limit="540" upper_limit="540"/>
                    <measurement group_id="O4" value="106.0" lower_limit="106" upper_limit="106"/>
                    <measurement group_id="O6" value="23.0" lower_limit="23" upper_limit="23"/>
                    <measurement group_id="O7" value="106.0" lower_limit="14" upper_limit="540"/>
                    <measurement group_id="O8" value="16.0" lower_limit="16" upper_limit="16"/>
                    <measurement group_id="O9" value="6.0" lower_limit="6" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="67"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" lower_limit="5" upper_limit="724"/>
                    <measurement group_id="O2" value="63.0" lower_limit="5" upper_limit="724"/>
                    <measurement group_id="O3" value="63.0" lower_limit="13" upper_limit="83"/>
                    <measurement group_id="O4" value="64.0" lower_limit="41" upper_limit="724"/>
                    <measurement group_id="O5" value="139.0" lower_limit="22" upper_limit="475"/>
                    <measurement group_id="O6" value="64.0" lower_limit="16" upper_limit="111"/>
                    <measurement group_id="O7" value="62.0" lower_limit="5" upper_limit="588"/>
                    <measurement group_id="O8" value="101.0" lower_limit="101" upper_limit="101"/>
                    <measurement group_id="O9" value="80.0" lower_limit="8" upper_limit="724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="7" upper_limit="369"/>
                    <measurement group_id="O2" value="75.0" lower_limit="7" upper_limit="369"/>
                    <measurement group_id="O4" value="67.0" lower_limit="25" upper_limit="130"/>
                    <measurement group_id="O5" value="153.0" lower_limit="102" upper_limit="204"/>
                    <measurement group_id="O6" value="70.0" lower_limit="26" upper_limit="98"/>
                    <measurement group_id="O7" value="71.5" lower_limit="7" upper_limit="369"/>
                    <measurement group_id="O8" value="114.0" lower_limit="114" upper_limit="114"/>
                    <measurement group_id="O9" value="39.5" lower_limit="16" upper_limit="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/Infusion Reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.5" lower_limit="22" upper_limit="561"/>
                    <measurement group_id="O2" value="291.5" lower_limit="22" upper_limit="561"/>
                    <measurement group_id="O7" value="22.0" lower_limit="22" upper_limit="22"/>
                    <measurement group_id="O9" value="561.0" lower_limit="561" upper_limit="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Resolution (Grades 3-4) of Select Adverse Events</title>
        <description>Median time to resolution (Grades 3-4) of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
        <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one select adverse event from the category</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Resolution (Grades 3-4) of Select Adverse Events</title>
          <description>Median time to resolution (Grades 3-4) of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one select adverse event from the category</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulmonary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="5" upper_limit="64"/>
                    <measurement group_id="O2" value="19.0" lower_limit="5" upper_limit="64"/>
                    <measurement group_id="O6" value="6.0" lower_limit="6" upper_limit="6"/>
                    <measurement group_id="O7" value="30.0" lower_limit="5" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="61"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="2" upper_limit="684"/>
                    <measurement group_id="O2" value="22.0" lower_limit="2" upper_limit="684"/>
                    <measurement group_id="O3" value="NA" lower_limit="8" upper_limit="437">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O4" value="107.5" lower_limit="18" upper_limit="666"/>
                    <measurement group_id="O5" value="25.0" lower_limit="6" upper_limit="437"/>
                    <measurement group_id="O6" value="14.0" lower_limit="6" upper_limit="183"/>
                    <measurement group_id="O7" value="23.0" lower_limit="2" upper_limit="684"/>
                    <measurement group_id="O8" value="5.0" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O9" value="12.0" lower_limit="4" upper_limit="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="4" upper_limit="690"/>
                    <measurement group_id="O2" value="24.0" lower_limit="4" upper_limit="690"/>
                    <measurement group_id="O3" value="20.0" lower_limit="10" upper_limit="186"/>
                    <measurement group_id="O4" value="67.0" lower_limit="67" upper_limit="67"/>
                    <measurement group_id="O5" value="8.0" lower_limit="5" upper_limit="44"/>
                    <measurement group_id="O6" value="17.5" lower_limit="4" upper_limit="690"/>
                    <measurement group_id="O7" value="24.0" lower_limit="8" upper_limit="455"/>
                    <measurement group_id="O8" value="15.0" lower_limit="15" upper_limit="15"/>
                    <measurement group_id="O9" value="28.0" lower_limit="4" upper_limit="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="3" upper_limit="66"/>
                    <measurement group_id="O2" value="23.0" lower_limit="3" upper_limit="66"/>
                    <measurement group_id="O3" value="11.0" lower_limit="11" upper_limit="11"/>
                    <measurement group_id="O4" value="7.0" lower_limit="7" upper_limit="7"/>
                    <measurement group_id="O6" value="23.0" lower_limit="23" upper_limit="23"/>
                    <measurement group_id="O7" value="11.0" lower_limit="3" upper_limit="60"/>
                    <measurement group_id="O8" value="NA" lower_limit="20" upper_limit="20">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O9" value="66.0" lower_limit="66" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="67"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" lower_limit="1" upper_limit="889"/>
                    <measurement group_id="O2" value="38.0" lower_limit="1" upper_limit="889"/>
                    <measurement group_id="O3" value="67.0" lower_limit="3" upper_limit="225"/>
                    <measurement group_id="O4" value="17.5" lower_limit="2" upper_limit="285"/>
                    <measurement group_id="O5" value="126.0" lower_limit="1" upper_limit="625"/>
                    <measurement group_id="O6" value="55.0" lower_limit="1" upper_limit="612"/>
                    <measurement group_id="O7" value="30.0" lower_limit="2" upper_limit="889"/>
                    <measurement group_id="O8" value="29.0" lower_limit="29" upper_limit="29"/>
                    <measurement group_id="O9" value="117.0" lower_limit="15" upper_limit="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="2" upper_limit="1223">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="3" upper_limit="1019">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="4" upper_limit="950">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="5" upper_limit="931">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="3" upper_limit="670">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="4" upper_limit="1019">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="514" upper_limit="514">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="4" upper_limit="627">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/Infusion Reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O7" value="2.0" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O9" value="7.0" lower_limit="7" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of an Adverse Event (AE)</title>
        <description>Resolution of an adverse event (AE) is defined as a participant experiencing complete resolution or improvement to the baseline of any grade AE including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
        <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one select adverse event from the category</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of an Adverse Event (AE)</title>
          <description>Resolution of an adverse event (AE) is defined as a participant experiencing complete resolution or improvement to the baseline of any grade AE including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one select adverse event from the category</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulmonary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="6" upper_limit="738"/>
                    <measurement group_id="O2" value="43.0" lower_limit="6" upper_limit="738"/>
                    <measurement group_id="O3" value="7.5" lower_limit="7" upper_limit="8"/>
                    <measurement group_id="O4" value="NA" lower_limit="55" upper_limit="302">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="7" upper_limit="371">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O6" value="19.0" lower_limit="6" upper_limit="62"/>
                    <measurement group_id="O7" value="43.0" lower_limit="7" upper_limit="738"/>
                    <measurement group_id="O9" value="NA" lower_limit="24" upper_limit="302">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="236"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="175"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="1" upper_limit="1016"/>
                    <measurement group_id="O2" value="18.0" lower_limit="1" upper_limit="1016"/>
                    <measurement group_id="O3" value="12.0" lower_limit="1" upper_limit="468"/>
                    <measurement group_id="O4" value="36.0" lower_limit="1" upper_limit="720"/>
                    <measurement group_id="O5" value="14.0" lower_limit="1" upper_limit="527"/>
                    <measurement group_id="O6" value="14.0" lower_limit="1" upper_limit="183"/>
                    <measurement group_id="O7" value="19.0" lower_limit="1" upper_limit="1016"/>
                    <measurement group_id="O8" value="5.0" lower_limit="1" upper_limit="22"/>
                    <measurement group_id="O9" value="36.0" lower_limit="2" upper_limit="645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="228"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" lower_limit="1" upper_limit="1175"/>
                    <measurement group_id="O2" value="88.0" lower_limit="1" upper_limit="1175"/>
                    <measurement group_id="O3" value="NA" lower_limit="5" upper_limit="1002">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O4" value="257.0" lower_limit="1" upper_limit="1011"/>
                    <measurement group_id="O5" value="84.0" lower_limit="5" upper_limit="1055"/>
                    <measurement group_id="O6" value="33.5" lower_limit="4" upper_limit="775"/>
                    <measurement group_id="O7" value="102.0" lower_limit="1" upper_limit="1175"/>
                    <measurement group_id="O8" value="46.0" lower_limit="15" upper_limit="625"/>
                    <measurement group_id="O9" value="59.5" lower_limit="2" upper_limit="952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="2" upper_limit="904"/>
                    <measurement group_id="O2" value="56.0" lower_limit="2" upper_limit="904"/>
                    <measurement group_id="O3" value="11.0" lower_limit="11" upper_limit="11"/>
                    <measurement group_id="O4" value="5.5" lower_limit="2" upper_limit="100"/>
                    <measurement group_id="O5" value="9.5" lower_limit="4" upper_limit="15"/>
                    <measurement group_id="O6" value="27.5" lower_limit="23" upper_limit="32"/>
                    <measurement group_id="O7" value="56.0" lower_limit="2" upper_limit="904"/>
                    <measurement group_id="O8" value="NA" lower_limit="20" upper_limit="20">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="66" upper_limit="603">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="128"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="1" upper_limit="1008"/>
                    <measurement group_id="O2" value="43.0" lower_limit="1" upper_limit="1008"/>
                    <measurement group_id="O3" value="80.5" lower_limit="3" upper_limit="225"/>
                    <measurement group_id="O4" value="20.5" lower_limit="3" upper_limit="1008"/>
                    <measurement group_id="O5" value="97.0" lower_limit="1" upper_limit="650"/>
                    <measurement group_id="O6" value="34.0" lower_limit="1" upper_limit="612"/>
                    <measurement group_id="O7" value="37.0" lower_limit="3" upper_limit="912"/>
                    <measurement group_id="O8" value="129.0" lower_limit="31" upper_limit="129"/>
                    <measurement group_id="O9" value="29.0" lower_limit="8" upper_limit="1008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="242"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="166"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="2" upper_limit="1223">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="2" upper_limit="1223">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="76" upper_limit="917">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="4" upper_limit="950">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="5" upper_limit="1139">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="2" upper_limit="759">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="4" upper_limit="1223">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="40" upper_limit="938">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="6" upper_limit="1060">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/Infusion Reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O7" value="1.0" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O9" value="1.0" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is defined from the time of first dosing date to the date of death. A participant who has not died will be censored at the last known date alive</description>
        <time_frame>Up to approximately 37 months</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is defined from the time of first dosing date to the date of death. A participant who has not died will be censored at the last known date alive</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="33.91" upper_limit="NA">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="34.76" upper_limit="NA">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O3" value="11.01" lower_limit="7.23" upper_limit="NA">Insufficient data due to insufficient participant follow up.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O5" value="12.55" lower_limit="3.78" upper_limit="33.91"/>
                    <measurement group_id="O6" value="15.21" lower_limit="10.41" upper_limit="21.42"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">KM methodology requires having more than 50% of events to estimate the median and/or upper/lower limits.</measurement>
                    <measurement group_id="O8" value="20.83" lower_limit="1.15" upper_limit="NA">Insufficient data due to insufficient participant follow up.</measurement>
                    <measurement group_id="O9" value="34.76" lower_limit="16.69" upper_limit="NA">Insufficient data due to insufficient participant follow up.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Participants With Adverse Events</title>
        <description>The assessment of safety is measured by the incidence of participants who experienced any grade of adverse events (AEs), treatment-related AEs, serious adverse events (SAEs), and deaths</description>
        <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Participants With Adverse Events</title>
          <description>The assessment of safety is measured by the incidence of participants who experienced any grade of adverse events (AEs), treatment-related AEs, serious adverse events (SAEs), and deaths</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events (AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533"/>
                    <measurement group_id="O2" value="477"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="64"/>
                    <measurement group_id="O7" value="365"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484"/>
                    <measurement group_id="O2" value="444"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="61"/>
                    <measurement group_id="O7" value="332"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="324"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="40"/>
                    <measurement group_id="O7" value="238"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="107"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Participants With Select Adverse Events</title>
        <description>The assessment of safety is measured by the incidence of participants who experienced any grade of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
        <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Participants With Select Adverse Events</title>
          <description>The assessment of safety is measured by the incidence of participants who experienced any grade of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="31"/>
                    <measurement group_id="O7" value="175"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="296"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="228"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="34"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="128"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="231"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="29"/>
                    <measurement group_id="O7" value="166"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/Infusion Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Participants With Laboratory Abnormalities - Liver</title>
        <description>Safety assessment is measured by the incidence of participants who experienced a liver laboratory abnormality in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Upper Limit of Normal (ULN)</description>
        <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one on-treatment measurement of the corresponding laboratory parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Participants With Laboratory Abnormalities - Liver</title>
          <description>Safety assessment is measured by the incidence of participants who experienced a liver laboratory abnormality in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Upper Limit of Normal (ULN)</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one on-treatment measurement of the corresponding laboratory parameter</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT OR AST &gt; 3XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="442"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="56"/>
                    <count group_id="O7" value="338"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="72"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT OR AST &gt; 5XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="442"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="56"/>
                    <count group_id="O7" value="338"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT OR AST &gt; 10XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="442"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="56"/>
                    <count group_id="O7" value="338"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT OR AST &gt; 20XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="442"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="56"/>
                    <count group_id="O7" value="338"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOTAL BILIRUBIN &gt; 2XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="442"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="56"/>
                    <count group_id="O7" value="338"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CONCURRENT ALT OR AST ELEVATION &gt; 3XULN; TOTAL BILIRUBIN &gt; 2XULN IN 1 DAY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="442"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="56"/>
                    <count group_id="O7" value="338"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CONCURRENT ALT OR AST ELEVATION &gt; 3XULN; TOTAL BILIRUBIN &gt; 2XULN IN 30 DAYS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="442"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="56"/>
                    <count group_id="O7" value="338"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Participants With Laboratory Abnormalities - Thyroid</title>
        <description>Safety assessment is measured by the incidence of participants who experienced a thyroid laboratory abnormality in Free T3 (FT3), Free T4 (FT4), Lower Limit of Normal (LLN)</description>
        <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one on-treatment TSH measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Participants With Laboratory Abnormalities - Thyroid</title>
          <description>Safety assessment is measured by the incidence of participants who experienced a thyroid laboratory abnormality in Free T3 (FT3), Free T4 (FT4), Lower Limit of Normal (LLN)</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups with at least one on-treatment TSH measurement</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="49"/>
                <count group_id="O7" value="313"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TSH &gt; ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="123"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="91"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &gt; ULN WITH TSH &lt;= ULN AT BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="79"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &gt;ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE &lt;LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="55"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &gt;ULN WITH ALL OTHER FT3/FT4 TEST VALUES &gt;= LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &gt; ULN WITH FT3/FT4 TEST MISSING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt; LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="124"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt;LLN WITH TSH &gt;= LLN AT BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="116"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt;LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE &gt; ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="72"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt;LLN WITH ALL OTHER FT3/FT4 TEST VALUES &lt;= ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="40"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt; LLN WITH FT3/FT4 TEST MISSING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>Objective response rate is defined as the percentage of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of all treated participants</description>
        <time_frame>Up to approximately 37 months</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>Objective response rate is defined as the percentage of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of all treated participants</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" lower_limit="40.2" upper_limit="48.8"/>
                    <measurement group_id="O2" value="46.1" lower_limit="41.6" upper_limit="50.7"/>
                    <measurement group_id="O3" value="30.9" lower_limit="19.1" upper_limit="44.8"/>
                    <measurement group_id="O4" value="52.4" lower_limit="36.4" upper_limit="68.0"/>
                    <measurement group_id="O5" value="43.8" lower_limit="26.4" upper_limit="62.3"/>
                    <measurement group_id="O6" value="9.4" lower_limit="3.5" upper_limit="19.3"/>
                    <measurement group_id="O7" value="51.2" lower_limit="46.0" upper_limit="56.5"/>
                    <measurement group_id="O8" value="30.0" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O9" value="43.5" lower_limit="31.0" upper_limit="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Progression free survival per investigator assessment is defined as radiological evidence of progression, significant clinical symptomatic progression, or the need to introduce a non-study drug therapy.</description>
        <time_frame>Up to approximately 37 months</time_frame>
        <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O2">
            <title>ECOG PS0-1</title>
            <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O3">
            <title>ECOG PS2</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O4">
            <title>Brain Metastasis</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O5">
            <title>Mucosal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O6">
            <title>Ocular/Uveal</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O7">
            <title>Cutaneous</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O8">
            <title>Acral</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Progression free survival per investigator assessment is defined as radiological evidence of progression, significant clinical symptomatic progression, or the need to introduce a non-study drug therapy.</description>
          <population>All treated participants and ECOG, Brain Metastasis, and Disease Subtype subgroups</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="365"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" lower_limit="3.45" upper_limit="6.77"/>
                    <measurement group_id="O2" value="5.45" lower_limit="3.78" upper_limit="7.69"/>
                    <measurement group_id="O3" value="2.46" lower_limit="1.77" upper_limit="3.75"/>
                    <measurement group_id="O4" value="3.35" lower_limit="1.81" upper_limit="NA">Insufficient data due to insufficient participant follow up.</measurement>
                    <measurement group_id="O5" value="2.94" lower_limit="2.53" upper_limit="8.74"/>
                    <measurement group_id="O6" value="2.83" lower_limit="2.73" upper_limit="4.63"/>
                    <measurement group_id="O7" value="6.77" lower_limit="4.67" upper_limit="10.45"/>
                    <measurement group_id="O8" value="2.56" lower_limit="1.15" upper_limit="8.48"/>
                    <measurement group_id="O9" value="5.22" lower_limit="2.76" upper_limit="27.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose to 30 days after last dose (up to approximately 37 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nivolumab + Ipilimumab Total</title>
          <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months</description>
        </group>
        <group group_id="E2">
          <title>Nivolumab + Ipilimumab ECOG PS0-1</title>
          <description>Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1 subgroup</description>
        </group>
        <group group_id="E3">
          <title>Nivolumab + Ipilimumab ECOG PS2</title>
          <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2 subgroup</description>
        </group>
        <group group_id="E4">
          <title>Nivolumab + Ipilimumab Brain Metastasis</title>
          <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Brain Metastasis subgroup</description>
        </group>
        <group group_id="E5">
          <title>Nivolumab + Ipilimumab Mucosal</title>
          <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Mucosal</description>
        </group>
        <group group_id="E6">
          <title>Nivolumab + Ipilimumab Ocular/Uveal</title>
          <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Ocular/Uveal</description>
        </group>
        <group group_id="E7">
          <title>Nivolumab + Ipilimumab Cutaneous</title>
          <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Cutaneous</description>
        </group>
        <group group_id="E8">
          <title>Nivolumab + Ipilimumab Acral</title>
          <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Acral</description>
        </group>
        <group group_id="E9">
          <title>Nivolumab + Ipilimumab Other</title>
          <description>Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months&#xD;
Then&#xD;
Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months&#xD;
Participants were grouped in to Disease Subtype subgroup Other</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="107" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="356" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="324" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="238" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="43" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Autoimmune pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Immune-mediated hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lymphocytic hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Primary adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Thyroiditis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Immune-mediated enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pancreatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Polyserositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Immune-mediated hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Haemophagocytic lymphohistiocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Alveolar osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Septic arthritis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Post procedural fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Jaw cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rheumatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="42" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Autoimmune neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Autonomic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Immune-mediated renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pulmonary haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Drug reaction with eosinophilia and systemic symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vein collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="503" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="453" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="61" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="347" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="57" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="69" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="73" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="52" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="61" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="224" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="154" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="105" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="60" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="129" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="21" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="91" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="69" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="59" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="57" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="85" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="52" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="40" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="87" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="47" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="78" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="40" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="102" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="59" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="49" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="54" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="365"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please Email:</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

